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OBJECTIVES: To identify predictors of in-hospital mortality in patients with acute myocardial infarction
undergoing pharmacoinvasive treatment.
METHODS: This was an observational, prospective study that included 398 patients admitted to a tertiary center
for percutaneous coronary intervention within 3 to 24 hours after thrombolysis with tenecteplase.
ClinicalTrials.gov: NCT01791764
RESULTS: The overall in-hospital mortality rate was 5.8%. Compared with patients who survived, patients who
died were more likely to be older, have higher rates of diabetes and chronic renal failure, have a lower left
ventricular ejection fraction, and demonstrate more evidence of heart failure (Killip class III or IV). Patients who
died had significantly lower rates of successful thrombolysis (39% vs. 68%; p= 0.005) and final myocardial blush
grade 3 (13.0% vs. 61.9%; p,0.0001). Based on the multivariate analysis, the Global Registry of Acute Coronary
Events score (odds ratio 1.05, 95% confidence interval (CI) 1.02-1.09; p= 0.001), left ventricular ejection fraction
(odds ratio 0.9, 95% CI 0.89-0.97; p= 0.001), and final myocardial blush grade of 0-2 (odds ratio 8.85, 95% CI
1.34-58.57; p= 0.02) were independent predictors of mortality.
CONCLUSIONS: In this prospective study that evaluated patients with ST-segment elevation myocardial
infarction treated by a pharmacoinvasive strategy, the in-hospital mortality rate was 5.8%. The Global Registry
of Acute Coronary Events score, left ventricular ejection fraction, and myocardial blush were independent
predictors of mortality in this high-risk group of acute coronary syndrome patients.
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& INTRODUCTION
Primary percutaneous coronary intervention (pPCI) is the
standard of care reperfusion therapy for patients with
evolving ST-segment elevation myocardial infarction
(STEMI) (1-3). Although individual centers have performed
pPCI for many years, a significant number of patients with
STEMI either do not receive this optimal treatment or do not
receive it in a timely manner due to the small number of
tertiary care centers with an around-the-clock (’24/7’)
service. Large urban centers and rural areas, where tertiary
care hospitals are restricted to specific regions, are less likely
to have the capacity to deliver this treatment to the
population as a whole (4).
Thus, a pharmacoinvasive treatment strategy has emerged
as an alternative for STEMI patients admitted to primary care
centers. A pharmacoinvasive strategy consists of the use of
intravenous thrombolytic therapy in a primary care center
followed by immediate transfer to a tertiary hospital, where
early, systematic coronary angiography and percutaneous
coronary angioplasty should be performed within 3 to
24 hours, even in cases of successful reperfusion (5).
In Brazil, despite recent social and medical therapeutic
advances, the number of acute myocardial infarctions in the
population still reaches 300,000 to 400,000 per year, with
STEMI representing 30% to 40% of all cases. Furthermore,
mortality rates are still high outside major referral centers,
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with an estimated 1 death for every 5 to 7 cases (6).
Therefore, we recently developed a public STEMI network
based on a pharmacoinvasive treatment strategy in the
metropolitan area of Sa˜o Paulo as a possible alternative to
pPCI. In the present study, we sought to evaluate the rate
and predictors of in-hospital mortality in a large population
of STEMI patients who underwent pharmacoinvasive
treatment.
& METHODS
Patients and study protocol
Between November 2010 and October 2012, 567 patients
with STEMI were transferred to a tertiary hospital (Hospital
Sa˜o Paulo, Escola Paulista de Medicina at Federal University
of Sa˜o Paulo) as part of a municipal primary care program
for STEMI. The structured health care network for patients
with STEMI has been previously described in detail
elsewhere (7). In brief, patients are first admitted to a
primary emergency room facility or rescued by the
Emergency Mobile Healthcare Service (SAMU) at home
and then referred to our tertiary PCI center. Patients were
either treated with thrombolysis or underwent pPCI as
appropriate and according to current guidelines (1-3). Those
patients receiving thrombolysis were referred for an early
invasive coronary angiography procedure regardless of
successful reperfusion 3 to 24 hours after thrombolysis
(i.e., elective or rescue PCI) according to clinical and
electrocardiographic criteria. Coronary angiographies were
performed by femoral access, and only bare metal stents
were used. After excluding patients who did not receive
thrombolysis, those who underwent pPCI, and those with
no acute myocardial infarction, 398 patients remained for
the present analysis.
Study objective and definitions
The primary objective of this study was to evaluate the
rate and predictors of in-hospital mortality in a population
of STEMI patients who underwent pharmacoinvasive
treatment. Patients were consecutively included and
divided into two groups according to mortality (patients
who died during the index hospitalization from all causes
and patients who survived) and compared according to
their clinical, angiographic, and procedural variables as
appropriate. Demographic and clinical data were entered
into a database prospectively, and all quantitative coronary
angiography data were analyzed by one experienced
interventional cardiologist. Thrombolysis in myocardial
infarction (TIMI) flow and blush grade were assessed as
previously reported (8,9). Coronary artery disease (CAD)
was defined as single- or multi-vessel disease according to
the number of epicardial arteries with at least 1 lesion
measuring $70% of the diameter of stenosis.
Chronic renal failure was defined as creatinine clearance
,60 mL/min, estimated by the Cockcroft-Gault formula
(10). Anemia was defined as plasma hemoglobin measuring
less than 13 mg/dL for males or 12 mg/dL for females (11).
The Global Registry of Acute Coronary Events (GRACE)
score (12) was calculated at admission, and the left
ventricular ejection fraction (LVEF) was determined by
echocardiography during hospitalization. Successful throm-
bolysis was defined as a culprit artery with TIMI flow grade
2-3 at the time of coronary angiography. Time intervals
between chest pain and the administration of Tenecteplase
(TNK; pain-to-needle time) and between the administration
of TNK and coronary angiography (needle-to-balloon time)
are expressed in hours. This study was conducted in
compliance with the ethical principles of the Helsinki
Declaration (2008), as well as local applicable laws and
regulations. It was registered in ClinicalTrials.gov with the
identifier number NCT01791764.
Statistical analysis
Continuous variables are expressed as the mean and
standard deviation, and categorical variables are expressed
as absolute numbers and percentages. Fisher’s exact test,
Pearson’s chi-square test, or Student’s t-test were used when
appropriate.
A multivariate logistic regression model was used to
identify potential independent predictors of mortality. Odds
ratios (ORs) and their respective confidence intervals (95%
CIs) were used to quantify the effects. The variables included
in the model were age, gender, hemoglobin level, diabetes
mellitus, hypertension, current smoking status, chronic renal
failure, GRACE score, Killip class, baseline and final TIMI
flow, and final myocardial blush grade. SPSSH software
version 20 (IBM, Armonk, NY, USA) was used for all analyses,
and a final p value less than 0.05 was considered significant.
& RESULTS
The study flowchart is shown in Figure 1. After excluding
pPCI patients, patients without CAD, patients triaged to
CABG, and patients treated with thrombolytics other than
TNK, a total of 398 patients were selected for the current
analysis. The mean pain-to-needle and needle-to-balloon
times were 4.5¡3.8 and 16.4¡20.6 hours, respectively.
Overall, the in-hospital mortality rate was 5.8% (compared
with 6.5% of the entire population of 567 patients), and the
mean GRACE score was 148.2¡36.9. A comparison of
demographic and clinical characteristics in non-survivors
and survivors is provided in Table 1. Compared with
patients who survived, non-survivors were more likely to be
older and to have higher rates of diabetes and chronic renal
failure, higher GRACE scores, lower LVEFs, and more
evidence of heart failure (Killip class III or IV). Additionally,
patients who died had a significantly lower incidence of
baseline TIMI grade 2 or 3 flow (39% vs. 68%; p= 0.005) and
a lower final myocardial blush grade (Table 1).
Two patients (0.5%) had a hemorrhagic stroke, 16 (4%)
required blood transfusion, and vascular complications
related to the access site were observed in 26 (6.5%) patients.
A more detailed analysis of the vascular access and bleeding
complications in patients undergoing pharmacoinvasive
strategy in our institution has been previously reported (13).
Predictors of in-hospital mortality
Based on the multivariate regression analysis, only
GRACE score, LVEF, and final blush grade 0-2 were
independent predictors of mortality (Table 2).
& DISCUSSION
Providing optimal care for STEMI patients is challenging
in any country, regardless of its wealth and developmental
level. This is especially true in large urban centers or rural
areas, where a lack of access to tertiary healthcare may make
the performance of timely pPCI difficult. The so-called
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pharmacoinvasive treatment strategy, consisting of throm-
bolysis with TNK and contemporary antithrombotic therapy
administered before transport to a PCI-capable hospital, has
emerged as an alternative to pPCI. The recommendation of
prompt transfer to a referral center with a catheterization
laboratory is deemed fundamental to the strategy’s success,
allowing for (i) immediate reperfusion in cases when
thrombolysis fails; (ii) treatment for early reocclusion, which
can affect as many as 30% of cases (14); and, ultimately, (iii)
early PCI (,24 hours) for patients with successful thrombo-
lytic reperfusion but with severe residual stenosis. Compared
with pPCI, this strategy has shown similar clinical outcomes
(15-17). Accordingly, this strategy is strongly recommended
by the European Society of Cardiology and ACC/AHA
guidelines (class I and IIa, respectively) (1,3).
The present study represents one of the largest real-world
studies relevant to this subject thus far and shows an in-
hospital all-cause mortality rate of 5.8%. Other national,
multicenter studies have reported mortality rates of 3.3% in
patients who underwent elective PCI after thrombolysis,
7.6% in patients who underwent rescue PCI, and 5.6% in
pPCI patients (18,19). In previous randomized multicenter
studies comparing a pharmacoinvasive strategy with
ischemia-driven PCI, in-hospital mortality rates ranged
from 3.0% to 4.5%. These studies, however, also demon-
strated shorter pain-to-needle and needle-to-balloon times
(2 and 4 hours, respectively), which may explain, at least in
part, their lower mortality rates (14,20). A remarkably low
mortality rate was also observed in a recently published
STREAM trial (21), which compared pPCI with a pharma-
coinvasive approach. This study randomized STEMI
patients who had a clinical presentation for less than
3 hours and who were at least 60 minutes away from
pPCI centers and found an overall mortality rate of 4.7% for
both groups. Similar to previous results, such as those
obtained in the TRANSFER AMI study (14), and our own
results, one-third of the STREAM patients required rescue
catheterization.
In the present analysis, LVEF and the GRACE score
emerged as significant predictors of mortality. Successful
thrombolysis was achieved in over 65% of patients, similar
to the rate reported in the STREAM trial, with a mortality
rate of only 3.4% in this subgroup (significantly lower than
the rate of 10.4% in patients with a baseline TIMI flow of 0-
1). Therefore, this study showing a low mortality rate in
patients who underwent successful thrombolysis is
encouraging and stresses the potential importance of a
pharmacoinvasive treatment strategy, especially in public
hospitals and developing countries.
Regardless of achieving a similar optimal final TIMI flow
after PCI (as a surrogate endpoint for PCI angiographic
success) in both groups, grade 3 myocardial blush was
observed significantly less often in non-survivors; thus,
myocardial blush grade was also an important independent
predictorof mortality. Restoring coronary microcirculation
through the use of several available strategies and in light of
ongoing studies (e.g., intracoronary abciximab and throm-
bectomy) has been a challenge for interventional cardiolo-
gists over the last several decades. Studies evaluating
patients who underwent thrombolytic and mechanical
reperfusion during STEMI showed a direct relationship
between the degree of myocardial perfusion, as detected by
the blush angiographic method, and mortality in short and
long clinical follow-up periods (22,23).
Restoring microcirculation extends beyond the restoration
of epicardial flow and depends on the optimization of
adjunctive therapy, especially antiplatelet and antithrombo-
tic therapy. Compared with the STREAM trial population,
we achieved similar rates of final TIMI flow 2-3 even in a
setting of a longer pain-to-needle time. Therefore, achieving
Figure 1 - Flowchart of patients included in the study.
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a baseline TIMI flow of 3 along with a myocardial blush
grade of 3 should be considered to indicate optimal
reperfusion. This finding is in accordance with previous
studies demonstrating a normal myocardial blush grade as
a predictor of survival and left ventricular recovery in
patients who undergo pPCI and rescue angioplasty (24-28).
Hemorrhagic complications are still a concern associated
with this strategy. However, no significant difference was
observed in randomized trials between this treatment
strategy and other treatments (14,20,21). In the STREAM
trial, after the amendment of halving the TNK dosage in
patients older than 75 years, there was no significant
difference in hemorrhagic events between the groups.
Hemorrhagic stroke and blood transfusion occurred in
0.5% and 2.9% of patients, respectively; in our study, these
rates were 0.5% and 4.0%, respectively.
Although far from ideal because pPCI is considered the
standard of care for STEMI patients, a pharmacoinvasive
treatment strategy could be an alternative for achieving
short pain-to-balloon times and, coupled with a structured
healthcare network, could represent a highly important
improvement in public health management of STEMI in
Brazil. The present study is a step forward in adjusting the
healthcare system in accordance with global standards to
optimally assist the largest possible number of patients.
This study has several limitations. It was an observational
and single-center study. A femoral artery approach was
used in all cases, and bleeding criteria may underestimate
the actual impact of this important complication on
mortality. In addition, the use of radial access in pPCI has
been associated with lower mortality rates (29,30). The
multivariate analysis performed in this study cannot
exclude residual confounding due to unmeasured or
unknown variables. Finally, the generalizability of this
study is limited because it can only be applied to STEMI
patients who undergo a pharmacoinvasive treatment
strategy according to the methods described in our protocol.
In this real-world, prospective study that included STEMI
patients who underwent a pharmacoinvasive treatment
strategy, in-hospital mortality rates were low at 5.8%. The
GRACE score, LVEF, and myocardial blush grade were
powerful predictors of mortality after administration of this
pharmacoinvasive treatment strategy in the contemporary
reperfusion era.
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